NYSE:NVRONevro Stock Price, Forecast & News

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVRO stock has increased by 7.2% and is now trading at $117.76. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nevro.

Nevro is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Nevro.

Nevro Corp (NYSE:NVRO) issued its earnings results on Tuesday, May, 5th. The medical equipment provider reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.21. The medical equipment provider had revenue of $87.47 million for the quarter, compared to the consensus estimate of $86.70 million. Nevro had a negative return on equity of 40.67% and a negative net margin of 21.36%. Nevro's revenue was up 6.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.45) EPS. View Nevro's earnings history.

12 brokerages have issued 1-year target prices for Nevro's shares. Their forecasts range from $65.00 to $158.00. On average, they anticipate Nevro's stock price to reach $120.83 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price. View analysts' price targets for Nevro.

Headlines about NVRO stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nevro earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news stories about the medical equipment provider a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an effect on the stock's share price in the next several days. View the latest news about Nevro.

Some companies that are related to Nevro include Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Novocure (NVCR), Tandem Diabetes Care (TNDM), Globus Medical (GMED), Haemonetics (HAE), Integra Lifesciences (IART), ICU Medical (ICUI), Inovio Pharmaceuticals (INO), Irhythm Technologies (IRTC), NuVasive (NUVA), Merit Medical Systems (MMSI) and Inspire Medical Systems (INSP). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Adobe (ADBE), AbbVie (ABBV), Trade Desk (TTD), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Shopify (SHOP) and Vertex Pharmaceuticals (VRTX).

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $117.76.

Nevro has a market capitalization of $4.00 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 804 workers across the globe.

The official website for Nevro is www.nevro.com.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]